Telix Pharmaceuticals (Est) Pty. Ltd.
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, is a pioneering biopharmaceutical company focused on the development of innovative cancer therapies and diagnostic imaging solutions. Founded in 2015, Telix has rapidly established itself in the oncology sector, with a strong emphasis on radiopharmaceuticals that target specific cancer types.
The company operates primarily in Australia, Europe, and North America, offering unique products such as TLX591 (a prostate cancer imaging agent) and TLX250 (for renal cancer). These therapies leverage advanced radiolabelled technology, setting Telix apart in a competitive market. With a commitment to improving patient outcomes, Telix Pharmaceuticals has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position as a leader in the field of targeted cancer treatment.
-19 vs industry average
Telix Pharmaceuticals (Est) Pty. Ltd.’s score of 20 is lower than 45% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Telix Pharmaceuticals (Est) Pty. Ltd.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Telix Pharmaceuticals (Est) Pty. Ltd. yet.
Telix Pharmaceuticals (Est) Pty. Ltd.'s reported carbon emissions
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, currently does not have specific emissions data available for the most recent year. As a current subsidiary of Telix Pharmaceuticals Limited, any climate commitments or emissions data may be influenced by the parent company's initiatives.
The company has not publicly disclosed any reduction targets or significant achievements related to carbon emissions. Furthermore, there are no specific climate pledges or commitments outlined in their current documentation.
As part of the broader pharmaceutical industry, Telix Pharmaceuticals is expected to align with emerging sustainability practices, but specific details regarding their carbon emissions and climate commitments remain unspecified at this time.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Telix Pharmaceuticals (Est) Pty. Ltd.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Telix Pharmaceuticals (Est) Pty. Ltd. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project